TRZYDE banner

TRZYDE

Translational Research of 3‑Dimensional Engineered Sarcoma Models

Discover the Timeline

Why TRZYDE?

Craniofacial osteo‑ and chondro‑sarcomas remain a therapeutic challenge: high local relapse rate, limited systemic options and scarce pre‑clinical models. Two‑dimensional cell lines fail to mimic extracellular matrix, while in‑vivo xenografts are costly and slow.

TRZYDE builds a rapid 3‑D bioprinted platform that replicates the tumour micro‑environment within days, enabling high‑throughput compound screening and mechanistic insight into the MDM2‑p53 axis.

SMART path

The project is being shaped for the upcoming NCBR "Ścieżka SMART – FENG 2021‑2027" call (Q3 2025). This EU‑backed programme funds industrial research and experimental development for Polish SMEs up to 80% of project value.

  • Budget window: €0.5 – 18 M per project
  • Evaluation: novelty, TRL progress, commercial impact
  • Planned TRZYDE ask: €2.1 M (TRL 3→6)

Compound Pipeline

Brigimadlin (BI‑907828)

Potent oral MDM2–p53 antagonist

  • ✓ Logistics validation
  • ✓ Purity & stability profiling
  • ⇢ Dose‑response 3‑D cytotoxicity (Q2 2025)

Milademetan (RAIN‑32)

Next‑gen MDM2 inhibitor (phase III)

  • ⇢ Procurement & analytics (Q3 2025)
  • ⇢ Comparative screen vs Brigimadlin
  • ⇢ Synergy mapping with radiation

Nutlin‑3a

Benchmark first‑generation MDM2 ligand

  • ✓ Positive control for assay calibration
  • ⇢ Mechanistic RNA‑seq signature
  • ⇢ p53 pathway phospho‑proteomics

Roadmap 2025 → 2026

Q2 2025 – Logistics & Analytics

Import test batch (BI‑907828), customs, HPLC‑MS validation.

Q3 2025 – 3‑D Bioprinting Setup

Establish GelMA scaffolds, live‑dead QC, baseline transcriptomics.

Q1 2026 – Multi‑Compound Screen

Brigimadlin dose‑response, Milademetan head‑to‑head, Nutlin‑3a calibration.

Q3 2026 – SMART Grant Submission

Full proposal to NCBR with preliminary IC50 data & imaging pipeline.

2026 – Scale‑up & Commercial Demo

TRL‑6 prototype ready for CRO contract screening and pharma partnerships.

Planned Partners

Warsaw Tech

National Oncology Institute

Radfarm Analytics